[The suppression test in the control of the course of antithyroid drug therapy: renaissance of an in vivo nuclear medicine procedure?].
Measurements of thyroidal suppressibility by thyroid hormones belong to the diagnostic program in nuclear medicine for more than 30 years. Suppression tests are used in follow-up of antithyroidal treatment to predict remission or relapse of hyperthyroidism. Recently, the number of publications dealing with suppression tests has been increasing. Apparently, non-suppressibility of the thyroid after antithyroidal treatment for about 1 year corresponds to a rate of relapse of about 70% whereas in the case of a positive suppression test, the relapse rate amounts to about 20% only. The diagnostic procedures described in the literature are different with respect to radiopharmaceuticals, activity doses, thyroid hormone suppression and, above all, to the time of uptake measurements. After a critical discussion of the literature, a modern diagnostic procedure for the suppression test is proposed using 123I or 99mTc and a computer-assisted gamma camera.
Reiners
C
C
Becker
W
W
Börner
W
W
D013956:Antithyroid Agents / Q000627:therapeutic use*; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy*; D007457:Iodine Radioisotopes; D011877:Radionuclide Imaging; D013667:Technetium; D013960:Thyroid Function Tests / Q000379:methods*; D013961:Thyroid Gland / Q000000981:diagnostic imaging*
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D013667:Technetium
Der Suppressionstest zur Verlaufskontrolle der thyreostatischen Therapie: Renaissance eines nuklearmedizinischen In-vivo-Verfahrens?